{"disease":{"id":"lassa-virus-infection","name":"lassa virus infection"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03783143","title":"Prevalence and Incidence of Lassa Virus Infection in Southern Mali","phase":"","overall_status":"COMPLETED","enrollment_count":8524,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03655561","title":"Lassa Fever Clinical Course and Prognostic Factors in Nigeria","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Alliance for International Medical Action","has_results":false},{"nct_id":"NCT02311387","title":"Seroprevalence and Incidence of Lassa Fever in the Rural Commune of Sibirila, District of Bougouni, Mali","phase":"","overall_status":"COMPLETED","enrollment_count":601,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT05735249","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Arisan Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04055454","title":"A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Themis Bioscience GmbH","has_results":false},{"nct_id":"NCT06911242","title":"A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed Conditions","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Arisan Therapeutics, Inc.","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}